Allosteric Lariat Peptide Inhibitors of Abl Kinase
Authors:
- 12 September 2013
- journal article
- research article
- Published by Wiley in ChemBioChem
- Vol. 14 (16) , 2119-2125
Abstract
Going against tradition: Although most kinase inhibitors are ATP competitive, lariat peptides inhibit Abl kinase activity in an ATP-uncompetitive manner. Further, lariat peptides discriminated Src family kinases, and recognize the allosteric region that lies adjacent to the ATP binding pocket in the Abl kinase catalytic cleft.Keywords
This publication has 34 references indexed in Scilit:
- Selection of cyclic-peptide inhibitors targeting Aurora kinase A: Problems and solutionsBioorganic & Medicinal Chemistry, 2011
- Biochemical Mechanisms of Resistance to Small-Molecule Protein Kinase InhibitorsACS Chemical Biology, 2010
- Taking the chemical out of chemical geneticsNature Chemical Biology, 2009
- Rapid selection of cyclic peptides that reduce α-synuclein toxicity in yeast and animal modelsNature Chemical Biology, 2009
- Protein kinase inhibitors: contributions from structure to clinical compoundsQuarterly Reviews of Biophysics, 2009
- Targeting cancer with small molecule kinase inhibitorsNature Reviews Cancer, 2009
- A General Strategy for Creating “Inactive-Conformation” Abl InhibitorsChemistry & Biology, 2006
- Rational design of inhibitors that bind to inactive kinase conformationsNature Chemical Biology, 2006
- Specific peptides for the therapeutic targeting of oncogenesCurrent Opinion in Genetics & Development, 2006
- Searching for new allosteric sites in enzymesCurrent Opinion in Structural Biology, 2004